Targeting the RB-pathway in Cancer Therapy

Feb 15, 2010 - and the RB status played a role in the response to flavopri- dol (63). However, such ... 6 http://www.cancer.gov/clinicaltrials. RB-Pat...

0 downloads 0 Views 297KB Size

Recommend Documents

was synthesized by combining domain1-3 of VEGFR-1 and the Fc portion of .... axitinib in patients with previously treated metastatic renal cell carcinoma was ...

REVIEW. Targeting survivin in cancer therapy: fulfilled promises and open questions ... extended C-terminal a-helical coiled-coil domain; it does not contain ... Growing evidence points to a functional role of survivin in both cell ..... within and k

May 31, 2017 - Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, et al. (2012) Mucin 16 (cancer .... GEICO--the MIMOSA study. J Clin Oncol 31: ...

Mar 3, 2012 - Figure 1: mRNA recruitment during translation initiation. (i) The eIF4F .... scanning or permitting the transfer of eIF4E from mRNAs that are .... The model may offer a starting point for a medicinal chemistry ... (A) 3D view of the int

Apr 4, 2017 - Tumor-associated hyaluronic acid (HA) and hyaluronidase. (HAase) system is .... addition. For apoptosis assay, cells were treated with sHA and.

ABSTRACT Apoptosis, or programmed cell death, is a mechanism by which cells undergo death to control cell proliferation or in response to DNA damage. The understanding of apoptosis has provided the basis for novel targeted therapies that can induce d

The midkine promoter has also proved use- ful for targeting ovarian cancer cells and pancreatic cells, as has the cyclooxygensae-2 gene promoter [132, 133].

Oct 15, 2009 - p53 function via a recombinant adenovirus encoding p53 (Ad- vexin ... proved for use in China and SCH 58500, phase I–III clinical trials; ref.

Jan 9, 2017 - Keywords: cancer; microRNA; gene therapy; oncogene; tumor .... Until now, some studies of tumor gene therapy targeting miRNA have ...

Jun 27, 2012 - The HER2-PI3K pathway is the one of the most mutated pathways in cancer. Several drugs targeting the major kinases of this pathway have ...

in DNA repair in cancer cells.(3). In this review, we will first outline the mechanism of the. DNA damage response. Next, we will describe the aberrations in DNA damage responses in human cancers. Finally, we will explain how different DNA damage res

Dec 1, 2009 - A novel oligoamine analog inhibitor of histone demethylases blocks colon ... SUMOylation, glycosylation, ubiquitlylation, and phosphoryla-.

Oct 3, 2017 - Lysosome-targeting agents in cancer therapy. Guido Kroemer1,2,3,4,5,6,7 and Lorenzo Galluzzi1,8,9. 1. Université Paris Descartes/Paris V, ...

Oct 15, 2009 - these include hSSB1 and the MRN complex (9, 10). Once acti- vated ATM phosphorylates downstream effector proteins to ini- tiate cell cycle ...

Jul 18, 2006 - S.; Metro, G.; Crino, L. Oncology (Williston Park), 2005, 19, 989 - ... Robinson, M.K.; Weiner, L.M.; Adams, G.P. Drug Development. Research ...

Jan 15, 2009 - Abdullaev Z, Bodrova ME, Chernyak BV, et al. A cytochrome c mutant with high electron transfer and antioxidant activities but devoid of ...

Apr 27, 2017 - inhibitor, ETP-46464 (ATR IC50 = 25 nM) was identified [67]. Poor pharmacokinetic properties, however prevented the further development of ETP-46464 into a viable clinical candidate. Further high throughput screening using ATR-specific

Feb 27, 2007 - Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE,. Pollock BH, Mundy GR, Sun L-Z (2006) Cancer Res 66:6714–6721.

Sep 15, 2014 - free radicals influence on nuclear DNA inducing processes of .... preventing damage of immune and hormonal systems as the links of defensive mechanism in ... promoting cancer disease treatment and cure of patient.

Abstract: Enhancer of Zeste Homolog 2 (EZH2) is the core component of the polycomb repressive complex 2 (PRC2), possessing the enzymatic activity in generating di/tri-methylated lysine 27 in his- tone H3. EZH2 has important roles during early develop

Dec 21, 2015 - Thus, mutant p53 is an attractive druggable target for cancer therapy. ...... drug affinity responsive target stability (DARTS) assays (123–125).

2Graduate School of Materials Science, Nara Institute of Science ... 4Reseach Institute of Natural Sciences, ... nese Cancer Research Resources Bank) were cultured in ...... Sica A, Allavena P, Mantovani A. Cancer related inflammation: the mac- ....

Jul 2, 2014 - acids, cyclic tetrapeptides, benzamides, aliphatic acids and electrophilic ketones according to their chemical structures (Table 2). These agents ...

Abstract: Cancer stem cells (CSCs) are defined as rare populations of tumor-initiating ... potential for targeting CSCs with oncolytic viruses, including herpes simplex virus-1, adeno- ..... conducted with oHSV, G207, and HSV1716, for patients.